GSS Stock Overview
Operates as a molecular diagnostic company in Australia, the Asia Pacific, Europe, the Middle East, Asia, and the Americas. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 6/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Genetic Signatures Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | AU$0.63 |
| 52 Week High | AU$0.85 |
| 52 Week Low | AU$0.38 |
| Beta | 0.062 |
| 1 Month Change | -10.00% |
| 3 Month Change | -8.70% |
| 1 Year Change | 40.00% |
| 3 Year Change | -57.43% |
| 5 Year Change | -36.68% |
| Change since IPO | 29.90% |
Recent News & Updates
Recent updates
Getting In Cheap On Genetic Signatures Limited (ASX:GSS) Might Be Difficult
Jun 14
After Leaping 42% Genetic Signatures Limited (ASX:GSS) Shares Are Not Flying Under The Radar
Mar 08A Look At The Fair Value Of Genetic Signatures Limited (ASX:GSS)
Nov 14Genetic Signatures Limited (ASX:GSS) Investors Are Less Pessimistic Than Expected
Oct 10One Genetic Signatures Limited (ASX:GSS) Analyst Just Made A Major Cut To Next Year's Estimates
Jun 29Genetic Signatures (ASX:GSS) Posted Healthy Earnings But There Are Some Other Factors To Be Aware Of
Feb 28AU$3.20: That's What Analysts Think Genetic Signatures Limited (ASX:GSS) Is Worth After Its Latest Results
Feb 25What Kind Of Shareholders Hold The Majority In Genetic Signatures Limited's (ASX:GSS) Shares?
Feb 07
What Does Genetic Signatures' (ASX:GSS) CEO Pay Reveal?
Jan 17Genetic Signatures' (ASX:GSS) Wonderful 522% Share Price Increase Shows How Capitalism Can Build Wealth
Dec 27Genetic Signatures (ASX:GSS) Is In A Strong Position To Grow Its Business
Dec 06Shareholder Returns
| GSS | AU Life Sciences | AU Market | |
|---|---|---|---|
| 7D | -5.3% | 0.6% | -2.0% |
| 1Y | 40.0% | 12.0% | 7.8% |
Return vs Industry: GSS exceeded the Australian Life Sciences industry which returned 12% over the past year.
Return vs Market: GSS exceeded the Australian Market which returned 7.8% over the past year.
Price Volatility
| GSS volatility | |
|---|---|
| GSS Average Weekly Movement | 7.3% |
| Life Sciences Industry Average Movement | 8.9% |
| Market Average Movement | 8.0% |
| 10% most volatile stocks in AU Market | 16.8% |
| 10% least volatile stocks in AU Market | 3.1% |
Stable Share Price: GSS has not had significant price volatility in the past 3 months compared to the Australian market.
Volatility Over Time: GSS's weekly volatility (7%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2001 | n/a | Allison Rossiter | www.geneticsignatures.com |
Genetic Signatures Limited operates as a molecular diagnostic company in Australia, the Asia Pacific, Europe, the Middle East, Asia, and the Americas. The company offers enteric bacteria, Enteroaggregative E.coli aggR and aaiC, enteric viral, enteric protozoan, enteric protozoan extended, enteric microsporidia, respiratory pathogen, SARS-CoV-2, SARS-CoV-2 respiratory plus, coronavirus, atypical respiratory, pertussis and PCP, parainfluenza 4, STI genital pathogen, extended spectrum beta-lactamase and carbapenemase producing organisms, viral meningitis, flavivirus dengue alphavirus, flavivirus reflex, dengue typing, and alphavirus reflex Detection kits under the EasyScreen name. Genetic Signatures Limited was incorporated in 2001 and is headquartered in Newtown, Australia.
Genetic Signatures Limited Fundamentals Summary
| GSS fundamental statistics | |
|---|---|
| Market cap | AU$143.06m |
| Earnings (TTM) | -AU$17.86m |
| Revenue (TTM) | AU$13.77m |
10.4x
P/S Ratio-8.0x
P/E RatioIs GSS overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| GSS income statement (TTM) | |
|---|---|
| Revenue | AU$13.77m |
| Cost of Revenue | AU$7.91m |
| Gross Profit | AU$5.86m |
| Other Expenses | AU$23.72m |
| Earnings | -AU$17.86m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.079 |
| Gross Margin | 42.53% |
| Net Profit Margin | -129.74% |
| Debt/Equity Ratio | 0% |
How did GSS perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/20 21:15 |
| End of Day Share Price | 2024/12/19 00:00 |
| Earnings | 2024/06/30 |
| Annual Earnings | 2024/06/30 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Genetic Signatures Limited is covered by 2 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Anubhav Saxena | Bell Potter |
| Thomas Wakim | Bell Potter |